Business Wire

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata

WALTHAM, Mass. & DUBLIN--(BUSINESS WIRE)--Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), ...
Nasdaq

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus

DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2, randomized, placebo-controlled trial to evaluate its development-stage ...
Nasdaq

Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal

Horizon Therapeutics plc HZNP announced that the phase II study evaluating its pipeline candidate, dazodalibep, for the treatment of Sjögren’s syndrome has met the primary endpoint in patients with ...
ksn.com

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

WALTHAM, Mass. and DUBLIN, Oct. 27, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc ...